Swiss data-driven medicine firm Sophia Genetics has developed a new artificial intelligence (AI) powered solution for liquid biopsies to enable early diagnosis and treatment of cancer, as well as to monitor the effectiveness of treatment.
The new solution utilises the analytical power of the firm’s AI called SOPHiA to assess the circulating tumour DNA (ctDNA) or circulating tumour cells (CTC) present in liquid samples such as blood, urine and cerebral spinal fluid.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new application is developed to provide a quick and less invasive alternative for patients.
The existing analytical solutions are reportedly not capable of considering the stability and low ctDNA levels of various samples, which led to less use of liquid biopsies in hospitals.
SOPHiA is said to address these concerns by providing a standardised DNA analysis approach, which builds on the network of 300 hospitals that are currently using the firm’s AI for genomic data analysis across 50 countries.
Sophia Genetics CEO and co-founder Jurgi Camblong said: “By applying SOPHiA’s state-of-the-art analytical power to liquid biopsies, clinicians can now leverage the collective intelligence of over 300 hospitals to help better diagnose, treat, and monitor cancer in a less invasive manner for patients.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSOPHiA is claimed to deliver crucial insights into tumour profiles, even in the presence of low ctDNA levels.
Unlike the detection of changes on an imaging scan, which takes months, SOPHiA facilitates quick, accurate analysis and monitoring of a tumour's progression from a simple blood test.
The approach can also be used in clinical trials to identify patients who are most likely to benefit from new treatments.
The results from the analysis are made available in the firm’s solid tumours and haematological malignancies platform called OncoPortal to allow interpretation of all the genetic variants identified in ctDNA using SOPHiA.
Accessible on the firm’s analytical platform called Sophia DDM, OncoPortal indicates the relation between human gene variants, disease causality, progression, drug efficacy and toxicity to enable better use of the data for providing personalised care to patients.
Image: Sophia Genetics injects AI in liquid biopsies. Photo: courtesy of Sophia Genetics.
